RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Crinetics Pharmaceuticals - Stock

Crinetics Pharmaceuticals EBIT 2024

Crinetics Pharmaceuticals EBIT

-287.75 M USD

Ticker

CRNX

ISIN

US22663K1079

WKN

A2JQTJ

In 2024, Crinetics Pharmaceuticals's EBIT was -287.75 M USD, a 29.26% increase from the -222.61 M USD EBIT recorded in the previous year.

The Crinetics Pharmaceuticals EBIT history

YEAREBIT (undefined USD)
2030e1.79
2029e1.3
2028e-0.02
2027e-0.2
2026e-0.31
2025e-0.31
2024e-0.29
2023-0.22
2022-0.17
2021-0.11
2020-0.07
2019-0.05
2018-0.03
2017-0.01
2016-0.01

Crinetics Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Crinetics Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Crinetics Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Crinetics Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Crinetics Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Crinetics Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Crinetics Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Crinetics Pharmaceuticals’s growth potential.

Crinetics Pharmaceuticals Revenue, Profit, and EBIT History

DateCrinetics Pharmaceuticals RevenueCrinetics Pharmaceuticals EBITCrinetics Pharmaceuticals Net Income
2030e3.09 B undefined1.79 B undefined1.36 B undefined
2029e1.06 B undefined1.3 B undefined370.28 M undefined
2028e412.55 M undefined-16.79 M undefined-5.63 M undefined
2027e177.68 M undefined-203.15 M undefined-184.6 M undefined
2026e50.24 M undefined-308.44 M undefined-301.08 M undefined
2025e14.42 M undefined-308.48 M undefined-306.9 M undefined
2024e2.13 M undefined-287.75 M undefined-285.63 M undefined
20234.01 M undefined-222.61 M undefined-214.53 M undefined
20224.74 M undefined-167.88 M undefined-163.92 M undefined
20211.08 M undefined-107.7 M undefined-107.64 M undefined
202070,000 undefined-74.95 M undefined-73.81 M undefined
20191.19 M undefined-53.83 M undefined-50.42 M undefined
20182.43 M undefined-28.71 M undefined-27.12 M undefined
20172.05 M undefined-9.13 M undefined-9.16 M undefined
2016590,000 undefined-6.04 M undefined-6.02 M undefined

Crinetics Pharmaceuticals stock margins

The Crinetics Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Crinetics Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Crinetics Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Crinetics Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Crinetics Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Crinetics Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Crinetics Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Crinetics Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Crinetics Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Crinetics Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Crinetics Pharmaceuticals Margin History

Crinetics Pharmaceuticals Gross marginCrinetics Pharmaceuticals Profit marginCrinetics Pharmaceuticals EBIT marginCrinetics Pharmaceuticals Profit margin
2030e0 %57.83 %44.07 %
2029e0 %122.74 %34.93 %
2028e0 %-4.07 %-1.36 %
2027e0 %-114.33 %-103.9 %
2026e0 %-613.97 %-599.32 %
2025e0 %-2,139.73 %-2,128.75 %
2024e0 %-13,496.5 %-13,397.4 %
20230 %-5,547.17 %-5,345.85 %
20220 %-3,541.77 %-3,458.23 %
20210 %-9,972.22 %-9,966.67 %
20200 %-107,071.42 %-105,442.86 %
20190 %-4,523.53 %-4,236.97 %
20180 %-1,181.48 %-1,116.05 %
20170 %-445.37 %-446.83 %
20160 %-1,023.73 %-1,020.34 %

Crinetics Pharmaceuticals Aktienanalyse

What does Crinetics Pharmaceuticals do?

Crinetics Pharmaceuticals Inc. is a leading biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare endocrine diseases and hormone-dependent tumors. The company was founded in 2008 by a team of experienced pharmacy professionals and is headquartered in San Diego, California. History Crinetics Pharmaceuticals was founded based on groundbreaking research in the field of endocrine diseases. The company aims to develop innovative therapies for rare endocrine diseases and hormone-dependent tumors that have been inadequately treated thus far. Crinetics draws on decades of experience and in-depth knowledge in the fields of endocrinology, neuroscience, and cancer research. Business model Crinetics is a research and development company specializing in the discovery, development, and commercialization of drugs for rare endocrine diseases. The company has an extensive portfolio of proprietary compounds based on novel mechanisms of action that are in various stages of development. Crinetics works closely with leading experts in the field of endocrinology and oncology to develop and commercialize groundbreaking new therapies. Different divisions Crinetics specializes in the research, development, and commercialization of products that can be used in rare endocrine diseases and hormone-dependent tumors. The company operates in various areas, including: - Acromegaly: Crinetics is developing a medication for the treatment of acromegaly, a rare disease caused by overproduction of growth hormone. - Cushing's syndrome: Crinetics is developing a medication for the treatment of Cushing's syndrome, a rare disease caused by overproduction of cortisol. - Hypoparathyroidism: Crinetics is developing a medication for the treatment of hypoparathyroidism, a rare disease characterized by insufficient production of parathyroid hormone. - Neuroendocrine tumors: Crinetics is developing a medication for the treatment of neuroendocrine tumors, a rare group of tumors that arise from neuroendocrine cells. Products Crinetics has an extensive portfolio of innovative products based on novel mechanisms of action that are in various stages of development. The company focuses on developing drugs that can be used in rare endocrine diseases and hormone-dependent tumors. Some of the notable products are: - CRN00808: CRN00808 is a medication that can help improve the body's monitoring system that regulates the release of growth hormones. It is currently in phase 2 clinical trials. - CRN01941: CRN01941 is a medication for the treatment of Cushing's syndrome. It has been developed to inhibit excessive production of cortisol and is currently in phase 2 clinical trials. - CRN04777: CRN04777 is a medication for the treatment of acromegaly. It has been developed to inhibit overproduction of growth hormone and is currently in phase 1 clinical trials. - CRN04894: CRN04894 is a medication for the treatment of hypoparathyroidism. It has been developed to stimulate parathyroid hormone production and is currently in phase 1 clinical trials. Conclusion Crinetics Pharmaceuticals is a leading biopharmaceutical company specializing in the development of innovative therapies for rare endocrine diseases and hormone-dependent tumors. The company has an extensive portfolio of proprietary compounds based on novel mechanisms of action that are in various stages of development. Crinetics works closely with leading experts in the field of endocrinology and oncology to develop and commercialize groundbreaking new therapies. Crinetics Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Crinetics Pharmaceuticals's EBIT

Crinetics Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Crinetics Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Crinetics Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Crinetics Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Crinetics Pharmaceuticals Stock

How much did Crinetics Pharmaceuticals achieve in EBIT for the current year?

In the current year, Crinetics Pharmaceuticals has achieved an EBIT of -287.75 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Crinetics Pharmaceuticals.

How has the EBIT of Crinetics Pharmaceuticals developed in recent years?

The EBIT of Crinetics Pharmaceuticals has increased by 29.261% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Crinetics Pharmaceuticals?

The EBIT of Crinetics Pharmaceuticals is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Crinetics Pharmaceuticals pay?

Over the past 12 months, Crinetics Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Crinetics Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Crinetics Pharmaceuticals?

The current dividend yield of Crinetics Pharmaceuticals is .

When does Crinetics Pharmaceuticals pay dividends?

Crinetics Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Crinetics Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Crinetics Pharmaceuticals located?

Crinetics Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Crinetics Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Crinetics Pharmaceuticals from 6/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/20/2024.

When did Crinetics Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/20/2024.

What was the dividend of Crinetics Pharmaceuticals in the year 2023?

In the year 2023, Crinetics Pharmaceuticals distributed 0 USD as dividends.

In which currency does Crinetics Pharmaceuticals pay out the dividend?

The dividends of Crinetics Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Crinetics Pharmaceuticals

Our stock analysis for Crinetics Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Crinetics Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.